五禽戏联合仑伐替尼对晚期肝恶性肿瘤患者治疗疗效及免疫功能影响

Treatment Effect and Immune Function of Wuqinxi and Lunavatinib in Patients with Advanced Liver Malignancy Influence

目的研究五禽戏联合仑伐替尼对晚期肝恶性肿瘤患者诊治效果及免疫功能影响。方法临床研究对象选择2018.06~2022.06在我科进行晚期肝癌诊治的患者60例,按照随机排列表法将其分为试验组和对照组,每组各30例。对照组患者使用仑伐替尼进行诊治,试验组患者在对照组基础上联合使用五禽戏进行诊治,观察两组患者淋巴细胞亚群、生活质量、肿瘤标志物、不良反应以诊治效果,并进行分析。结果试验组患者诊治后CD4和CD4/CD8值及NK细胞活性高于诊治前,对照组较治疗前明显下降,且试验组淋巴细胞亚群相对于对照组更高;试验组患者卡氏功能状态(KPS)评分总有效率(90.00%)相对于对照组(63.33%)更高(P<0.05);诊治前两组患者甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原19-9(CA199)及肿瘤大小基本相同(P>0.05),诊治后试验组各项肿瘤标志物指标及肿瘤直径相对于对照组更低(P<0.05);试验组不良反应总发生率(16.67%)相对于对照组(50.00%)更低(P<0.05);试验组患者诊治总有效率(96.67%)相对于对照组(80.00%)更高(P<0.05)。结论针对晚期肝恶性肿瘤患者采取仑伐替尼联合五禽戏进行诊治,有利于改善患者淋巴细胞亚群情况、提高患者生活质量、改善患者肿瘤标志物指标、减少患者不良反应发生以及提高患者整体诊治有效率,具有临床应用价值,提倡推广使用。

Objective To study the effect of wuqinxi and lunvatinib on immune function in patients with advanced liver malignancy.Methods The clinical research subjects selected 60 patients with diagnosis and treatment of advanced liver cancer in our department from 2018 to 2022,and they were divided into test group and control group according to the random arrangement table method,with 30 cases in each group.Patients in the control group used lunvatinib for diagnosis and treatment,and patients in the test group used wuqinxi on the basis of the control group.The lymphocyte subsets,quality of life,tumor markers and adverse reactions of the patients in the two groups were observed,and the diagnosis and treatment effect was analyzed.Results The values of CD4 and CD4/CD8 and NK cell activity were higher after the previous treatment of the test group,and the control group had higher functional status(KPS)scoretotal effective rate(90.00%)higher than the control group(63.33%)(P<0.05);alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),sugar antigen 19-9(CA199)And the tumor size was basically the same(P>0.05),and the tumor marker index and tumor diameter of the test group after diagnosis and treatment were lower than that of the control group(P<0.05);The overall incidence of adverse reactions(16.67%)was lower than the control group(50.00%)(P<0.05),and the overall response rate(96.67%)was higher than the control group(80.00%)(P<0.05).Conclusion For advanced liver malignancy patients take wuqinxi,is helpful to improve lymphocyte subgroup in patients,improve the quality of life,improve patients tumor marker index,reduce adverse reactions in patients and improve the overall diagnosis and treatment of patients,has clinical application value,advocate the use.